Article

Proteomic analysis in monocytes of antiphospholipid syndrome patients: Deregulation of proteins related to the development of thrombosis

Hospital Universitario Reina Sofía, Córdoba, Spain.
Arthritis & Rheumatology (Impact Factor: 7.87). 09/2008; 58(9):2835-44. DOI: 10.1002/art.23756
Source: PubMed

ABSTRACT Antiphospholipid antibodies (aPL) are closely related to the development of thrombosis, but the exact mechanism(s) leading to thrombotic events remains unknown. In this study, using proteomic techniques, we evaluated changes in protein expression of monocytes from patients with antiphospholipid syndrome (APS) related to the pathophysiology of the syndrome.
Fifty-one APS patients were included. They were divided into 2 groups: patients with previous thrombosis, and patients with recurrent spontaneous abortion. As controls, we studied patients with thrombosis but without aPL, and age- and sex-matched healthy subjects.
The proteins that were more significantly altered among monocytes from APS patients with thrombosis (annexin I, annexin II, protein disulfide isomerase, Nedd8, RhoA proteins, and Hsp60) were functionally related to the induction of a procoagulant state as well as to autoimmune-related responses. Proteins reported to be connected to recurrent spontaneous abortion (e.g., fibrinogen and hemoglobin) were also determined to be significantly deregulated in APS patients without thrombosis. In vitro treatment with IgG fractions purified from the plasma of APS patients with thrombosis changed the pattern of protein expression of normal monocytes in the same way that was observed in vivo for monocytes from APS patients with thrombosis.
For the first time, proteomic analysis has identified novel proteins that may be involved in the pathogenic mechanisms of APS, thus providing potential new targets for pathogenesis-based therapies for the disease.

Download full-text

Full-text

Available from: Nuria Barbarroja, Apr 02, 2014
0 Followers
 · 
85 Views
  • Source
    • "Cancer PDI P Endometrial cancer (with NS-398 treatment) [243] ERp57 P Prostate cancer (metastatic cell lines) [244] PDI, ERp57 P Leukemia (with ascorbate or photodynamic therapy) [245] [246] ERp57 P Esophageal cancer (cell lines) [247] ERp57, PDI P, I, G Gastric cancer (cancer/metastases vs control tissues; in serum, after vs before operation; in chemotherapy-resistant vs nonresistant cells) [248] [249] [250] PDI P, G Human bladder transitional carcinoma (cells) [251] PDIp I Pancreatic cancer (cell lines) [252] ERp57 P, I Glioblastoma multiforme (in astrocytomas) [253] ERp57 P, I Malignant follicular thyroid carcinoma [254] ERp57 P Lung metastatic cancer (cell lines) [255] Neurologic PDI, ERp44 I Neurodegenerative diseases (in ts1-infected astrocytes) [256] PDI P, I Neurologic dysfunction (in immunodeficiency mouse model) [257] PDI G Traumatic brain injury (in rat model) [258] Inflammation PDI P, I Edematous pancreatitis (in acinar cells) [259] ERp57 P Acute colitis (in colonic mucosa) [260] Others PDI P, I Osteoporosis (in osteoblasts or in circulating monocytes) [261] [262] ERp57 G Toxin exposure (diethylhexyl phthalate, in liver) [263] PDI P Exposure to arsenic and ionizing radiation (in keratinocytes) [264] ERp57 P Chronic vestibular compensation (after unilateral labyrinthectomy) [265] PDI P, I, G Antiphospholipid syndrome (in monocytes) [266] ERp57, ERp46, ERp29 P, I Insulin resistance and dyslipidemia (in hepatocytes) [229] ERp72, ERp57 P Caloric restriction (in liver) [201] ERp57 P Idiopathic pulmonary fibrosis (in bronchoalveolar fluid) [267] PDI P Obstructive sleep apnea syndrome (in kidney) [242] ERp57 P Preeclamptic trophoblasts [217] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Thiol proteins may potentially act as redox signaling adaptor proteins, adjusting reactive oxygen species intermediates to specific signals and redox signals to cell homeostasis. In this review, we discuss redox effects of protein disulfide isomerase (PDI), a thioredoxin superfamily oxidoreductase from the endoplasmic reticulum (ER). Abundantly expressed PDI displays ubiquity, interactions with redox and nonredox proteins, versatile effects, and several posttranslational modifications. The PDI family contains >20 members with at least some apparent complementary actions. PDI has oxidoreductase, isomerase, and chaperone effects, the last not directly dependent on its thiols. PDI is a converging hub for pathways of disulfide bond introduction into ER-processed proteins, via hydrogen peroxide-generating mechanisms involving the oxidase Ero1α, as well as hydrogen peroxide-consuming reactions involving peroxiredoxin IV and the novel peroxidases Gpx7/8. PDI is a candidate pathway for coupling ER stress to oxidant generation. Emerging information suggests a convergence between PDI and Nox family NADPH oxidases. PDI silencing prevents Nox responses to angiotensin II and inhibits Akt phosphorylation in vascular cells and parasite phagocytosis in macrophages. PDI overexpression spontaneously enhances Nox activation and expression. In neutrophils, PDI redox-dependently associates with p47phox and supports the respiratory burst. At the cell surface, PDI exerts transnitrosation, thiol reductase, and apparent isomerase activities toward targets including adhesion and matrix proteins and proteases. Such effects mediate redox-dependent adhesion, coagulation/thrombosis, immune functions, and virus internalization. The route of PDI externalization remains elusive. Such multiple redox effects of PDI may contribute to its conspicuous expression and functional role in disease, rendering PDI family members putative redox cell signaling adaptors.
    Free Radical Biology and Medicine 03/2012; 52(9):1954-69. DOI:10.1016/j.freeradbiomed.2012.02.037 · 5.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atherosclerosis (AT) and cardiovascular disease (CVD) are enhanced in autoimmune diseases such as antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). The reason for this accelerated process is still debatable and, although traditional risk factors are more prevalent in those patients than in general population, they do not fully explain that enhanced risk. Inflammatory components of the immune response, mainly interleukins, TNF-α, and IFN-γ, as well as some autoantibodies, including anti-oxidized low density lipoproteins (anti-oxLDL), anti-beta-2-Glycoprotein 1 (anti- β2GPI), anti-Heat shock proteins 60/65 (anti-HSP60/65), and anti-oxLDL/β2GPI have been shown to play a leading role in the pathogenesis of both, AT and CVD. However, the role of the autoantibodies in accelerated AT in autoimmune disease patients is still controversial. Recently, DNA microarray and proteomic-based approaches have made substantial breakthrough into the study of various rheumatic diseases, thus allowing for the discovery of previously unknown proteins involved in CVD including some that may be suitable to be used as biomarkers. Herein, we review recent genomics and proteomic approaches that have been applied to the study of autoimmune diseases with atherosclerotic and CV risk. The pharmacogenomics and pharmacoproteomics studies given over to the analysis of ancient and new drugs used to relieve the physiopathology associated to these complex diseases are also discussed. Copyright © 2009 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.
    PROTEOMICS - CLINICAL APPLICATIONS 02/2009; 3(2):213 - 225. DOI:10.1002/prca.200800147 · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infection causes lung failure characterized by atypical pneumonia. We previously showed that antibodies against SARS-CoV spike domain 2 (S2) in the patient sera can cross-react with human lung epithelial cells; however, the autoantigen is not yet identified. In this study, we performed proteomic studies and identified several candidate autoantigens recognized by SARS patient sera in human lung type II epithelial cell A549. Among the candidate proteins, annexin A2, which was identified by mass spectrometry analysis and had the highest score by Mascot data search, was further characterized and investigated for its role as an autoantigen. By confocal microscopic observation, SARS patient sera and anti-S2 antibodies were co-localized on A549 cells and both of them were co-localized with anti-annexin A2 antibodies. Anti-annexin A2 antibodies bound to purified S2 proteins, and anti-S2 bound to immunoprecipitated annexin A2 from A549 cell lysate in a dose-dependent manner. Furthermore, an increased surface expression and raft-structure distribution of annexin A2 was present in A549 cells after stimulation with SARS-induced cytokines interleukin-6 and interferon-gamma. Cytokine stimulation increased the binding capability of anti-S2 antibodies to human lung epithelial cells. Together, the upregulated expression of annexin A2 by SARS-associated cytokines and the cross-reactivity of anti-SARS-CoV S2 antibodies to annexin A2 may have implications in SARS disease pathogenesis.
    Molecular Immunology 12/2009; 47(5):1000-9. DOI:10.1016/j.molimm.2009.11.019 · 3.00 Impact Factor
Show more